Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome

Citations of this article
Mendeley users who have this article in their library.


Objective: Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu++-mediated oxidation in patients with metabolic syndrome. Methods and results: This is a randomized double-blind, placebo-controlled study with cross-over and includes a 4-week wash-out period between the two treatment periods. At the end of each 8-week treatment period, subjects were challenged with a standardized mixed meal followed by blood collection over the ensuing 6h. Plasma lipoproteins were isolated by a combination of ultracentrifugation and FPLC for the continuous monitoring of conjugated dienes formation as an assessment of oxidative susceptibility. Fasting plasma TG was reduced by 20% (p<0.0002) and there was a modest reduction in hsCRP (6.1%, p<0.06). There was no change in either HDLc or LDLc in these subjects. Postprandial lipemia was reduced with ABT-335 as demonstrated by a 28.5% reduction ( p<0.0005) in incremental area under the curve for TG during the 6-hperiod after the meal challenge. Lag times for both fasting LDL (+16%) and postprandial LDL (+28%) were increased with the ABT-335 therapy, suggestive of reduced oxidative susceptibility. Co-incubation with autologous HDL did not reduced LDL oxidative susceptibility in these patients. Conclusion: ABT-335 therapy reduced fasting and postprandial triglycerides in patients with metabolic syndrome. Autologous HDL may be dysfunctional in these patients as co-incubation with HDL failed to reduce oxidative susceptibility of LDL. During ABT-335 therapy, LDL was less susceptible to Cu++-mediated oxidative modification, in spite of the lack of changes in LDLc levels. © 2013.




Le, N. A., Farkas-Epperson, M., Sweeney, M. E., Wilson, P. W. F., & Virgil Brown, W. (2013). Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. Atherosclerosis, 231(2), 268–273. https://doi.org/10.1016/j.atherosclerosis.2013.09.022

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free